Kymera Therapeutics (KYMR) is down roughly 4% Thursday after reporting first-quarter 2026 financial results and providing a business update. The move looks driven by investors rotating out despite headline beats, with attention on continued net losses and the cost ramp required to push multiple immunology degraders forward in the clinic. (investors.kymeratx.com)

For Q1 2026, Kymera posted revenue of about $34.36 million and an EPS loss of $0.71, both better than consensus expectations in published market summaries, with collaboration activity cited as a key driver of the revenue upside. Even with the beat, the company continues to operate at a loss while funding expanding R&D efforts, a setup that can pressure shares when traders prioritize near-term cash burn over longer-dated pipeline value. (investing.com)

Kymera has emphasized a multi-program clinical push (including its KT-621 STAT6 degrader franchise), which implies sustained R&D spending over coming quarters. Separately, Kymera put in place a $500 million at-the-market (ATM) equity program earlier in 2026, which can create an incremental dilution overhang even when not actively used, and the company has also seen routine insider-related SEC filings in April 2026 that can heighten sensitivity around supply. (stocktitan.net)

Key catalysts include updates to clinical timelines and any milestone recognition tied to the Gilead collaboration highlighted in today’s earnings materials, plus any signs the company taps its ATM program. Traders will also watch whether the post-earnings decline stabilizes as investors refocus on upcoming clinical readouts and program advancement milestones. (investing.com)